1
|
Szkudelska K, Chan MH, Okulicz M, Jasaszwili M, Lukomska A, Malek E, Shah M, Sunder S, Szkudelski T. Betaine supplementation to rats alleviates disturbances induced by high-fat diet: pleiotropic effects in model of type 2 diabetes. J Physiol Pharmacol 2021; 72. [PMID: 35288478 DOI: 10.26402/jpp.2021.5.11] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Received: 09/17/2021] [Accepted: 10/30/2021] [Indexed: 11/03/2022]
Abstract
Betaine is a biologically active compound exerting beneficial effects in the organism, however, the exact mechanisms underlying its action are not fully elucidated. The present study aimed to explore, whether betaine alleviates disorders induced by feeding rats a high-fat diet (HFD). Rats were divided into 3 groups: control, fed an HFD and fed an HFD and receiving betaine (2% water solution for 8 weeks). Betaine improved glucose tolerance, decreased blood levels of non-esterified fatty acids and prevented lipid accumulation in the skeletal muscle of rats on an HFD. Betaine reduced activities of blood alanine aminotransferase, blood levels of bilirubin and hepatic lipid content. Expression of fatty acid synthase in the liver and the skeletal muscle was decreased in response to feeding an HFD, and this effect was deepened by betaine in the muscle tissue. Hepatic and muscular expression of genes related to insulin signaling were unchanged in HFD-fed rats. Lipolysis stimulated by epinephrine (an adrenergic receptor agonist), forskolin (an activator of adenylate cyclase), dibutyryl-cAMP (an activator of protein kinase A) and DPCPX (an adenosine A1 receptor antagonist) was diminished in the adipocytes of rats fed an HFD, however, this effect was alleviated by betaine. Moreover, blood leptin levels in HFD-fed rats were elevated, whereas leptinemia have normalized by betaine supplementation. Betaine prevented the increase in expression of N-methyl D-aspartate receptors in the hippocampus and in the cerebral cortex. These results indicate that betaine positively affects the insulin-sensitive tissues: liver (hepatoprotective effects), skeletal muscle (reduced lipid accumulation) and adipose tissue (a rise in lipolysis), which is associated with improved insulin sensitivity. Betaine-induced prevention of hyperleptinemia indicates restoration of leptin action, and changes in the brain reveal neuroprotective properties. Our results show that betaine induces positive changes in HFD-fed rats, its action is pleiotropic and involves different tissues.
Collapse
Affiliation(s)
- K Szkudelska
- Department of Animal Physiology, Biochemistry and Biostructure, Poznan University of Life Sciences, Poznan, Poland
| | - M H Chan
- Research Center for Mind, Brain, and Learning, National Changchi University, Taipei City, Taiwan.,Institute of Neuroscience, National Chengchi University, Taipei, Taiwan
| | - M Okulicz
- Department of Animal Physiology, Biochemistry and Biostructure, Poznan University of Life Sciences, Poznan, Poland
| | - M Jasaszwili
- Department of Animal Physiology, Biochemistry and Biostructure, Poznan University of Life Sciences, Poznan, Poland
| | - A Lukomska
- Department of Preclinical Sciences and Infectious Diseases, Poznan University of Life Sciences, Poznan, Poland
| | - E Malek
- Department of Preclinical Sciences and Infectious Diseases, Poznan University of Life Sciences, Poznan, Poland
| | - M Shah
- Department of Animal Physiology, Biochemistry and Biostructure, Poznan University of Life Sciences, Poznan, Poland
| | - S Sunder
- Department of Animal Physiology, Biochemistry and Biostructure, Poznan University of Life Sciences, Poznan, Poland
| | - T Szkudelski
- Department of Animal Physiology, Biochemistry and Biostructure, Poznan University of Life Sciences, Poznan, Poland.
| |
Collapse
|
2
|
Aoun F, Malek E, Kazan D, Albisinni S, Peltier A, Bollens R, Roumeguère T. Management of chronic testicular pain due to thoracolumbar junction syndrome: A pilot study. Prog Urol 2020; 30:114-118. [PMID: 31980366 DOI: 10.1016/j.purol.2019.12.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2019] [Revised: 12/05/2019] [Accepted: 12/14/2019] [Indexed: 10/25/2022]
Abstract
INTRODUCTION Thoracolumbar dysfunction (TLD) had been evoked as a possible etiology of chronic testicular pain. Our study investigated the efficacy of osteopathic diagnosis and treatment of TLD in men with chronic testicular pain. METHODS Patients suffering from testicular pain were examined for thoracolumbar dysfunction and enrolled in a prospective trial if they have both conditions. Following standardized examination, all patients were prescribed 1 to 3 osteopathic treatment sessions, usually at weekly interval. Treatment success was evaluated using the Visual Analog scale and durability was assessed by regular follow-up. Patient satisfaction was also assessed. Comparison of pain improvement was done using Wilcoxon matched-pairs signed-ranks test. Logistic regression was used to assess for risk factors of success. A P<0.001 was used for significance. RESULT Out of 62 patients enrolled, 41 patients (median age 32 years, IQR 24-37) were suffering from chronic testicular pain and TLD. 37 of the 41 participants completed the treatment and follow-up according to the plan. Patients underwent a median of 2 osteopathic treatment sessions (range 1-3). Overall, pain disappeared completely in 25 patients (67.5%) and improvement was noted in 7 patients (18.9%). After initial improvement, two patients experienced relapse at their last visit (5.4%). Five patients (13.5%) had no improvement of their symptoms after osteopathic treatment. Statistically, improvement was significant with a P<0.001 and on logistic regression, site of pain and duration of pain were the sole predictors of failure. CONCLUSION TLD is a pathology that should be considered in the differential diagnosis in patients with chronic testicular pain and osteopathic manipulation of the spine appears to be an effective treatment option.
Collapse
Affiliation(s)
- F Aoun
- Urology department, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Urology department, Hôtel Dieu de France, Université Saint-Joseph, Lebanon.
| | - E Malek
- Osteopathic Medicine department, Levant Hospital, Lebanon
| | - D Kazan
- Urology department, Hôtel Dieu de France, Université Saint-Joseph, Lebanon
| | - S Albisinni
- Urology department, Cliniques Universitaires de Bruxelles, hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium
| | - A Peltier
- Urology department, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - R Bollens
- Urology department, Centre Hospitalier de Wallonie picarde, Belgium
| | - T Roumeguère
- Urology department, Cliniques Universitaires de Bruxelles, hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium
| |
Collapse
|
3
|
Caimi P, Reese-Koc J, Otegbeye F, Schneider D, Chamoun K, Boughan K, Cooper B, Galloway E, Gallogly M, Kruger W, Worden A, Kadan M, Malek E, Metheny L, Tomlinson B, Wald D, Sekaly R, Orentas R, Dropulic B, de Lima M. PHASE 1 STUDY OF ANTICD19 CAR-T CELLS WITH TNFα TRANSMEMBRANE DOMAIN AND 41BB, CD3ζ COSTIMULATORY DOMAINS. RESPONSES IN SUBJECTS WITH RAPIDLY PROGRESSIVE LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.115_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- P.F. Caimi
- Medicine - Hematology and Oncology; University Hospitals Seidman Cancer Center; Cleveland United States
| | - J.S. Reese-Koc
- Medicine - Hematology and Oncology; University Hospitals Seidman Cancer Center; Cleveland United States
| | - F. Otegbeye
- Medicine - Hematology and Oncology; University Hospitals Seidman Cancer Center; Cleveland United States
| | - D. Schneider
- Miltenyi Biotec Company; Lentigen; Gaithersburg United States
| | - K. Chamoun
- Medicine - Hematology and Oncology; University Hospitals Seidman Cancer Center; Cleveland United States
| | - K.M. Boughan
- Medicine - Hematology and Oncology; University Hospitals Seidman Cancer Center; Cleveland United States
| | - B.W. Cooper
- Medicine - Hematology and Oncology; University Hospitals Seidman Cancer Center; Cleveland United States
| | - E. Galloway
- Medicine - Hematology and Oncology; University Hospitals Seidman Cancer Center; Cleveland United States
| | - M.M. Gallogly
- Medicine - Hematology and Oncology; University Hospitals Seidman Cancer Center; Cleveland United States
| | - W. Kruger
- Miltenyi Biotec Company; Lentigen; Gaithersburg United States
| | - A. Worden
- Miltenyi Biotec Company; Lentigen; Gaithersburg United States
| | - M. Kadan
- Miltenyi Biotec Company; Lentigen; Gaithersburg United States
| | - E. Malek
- Medicine - Hematology and Oncology; University Hospitals Seidman Cancer Center; Cleveland United States
| | - L. Metheny
- Miltenyi Biotec Company; Lentigen; Gaithersburg United States
| | - B. Tomlinson
- Medicine - Hematology and Oncology; University Hospitals Seidman Cancer Center; Cleveland United States
| | - D.N. Wald
- Medicine - Hematology and Oncology; University Hospitals Seidman Cancer Center; Cleveland United States
| | - R.P. Sekaly
- Department of Pathology; Case Western Reserve University; Cleveland United States
| | - R. Orentas
- Miltenyi Biotec Company; Lentigen; Gaithersburg United States
| | - B. Dropulic
- Miltenyi Biotec Company; Lentigen; Gaithersburg United States
| | - M. de Lima
- Medicine - Hematology and Oncology; University Hospitals Seidman Cancer Center; Cleveland United States
| |
Collapse
|
4
|
Morschhauser F, Dekyndt B, Baillet C, Barthélémy C, Malek E, Fulcrand J, Bigot P, Huglo D, Décaudin B, Simon N, Odou P. A new pharmacokinetic model for 90Y-ibritumomab tiuxetan based on 3-dimensional dosimetry. Sci Rep 2018; 8:14860. [PMID: 30291297 PMCID: PMC6173718 DOI: 10.1038/s41598-018-33160-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2018] [Accepted: 09/07/2018] [Indexed: 02/01/2023] Open
Abstract
Monoclonal antibodies (mAbs) are key components in several therapies for cancer and inflammatory diseases but current knowledge of their clinical pharmacokinetics and distribution in human tissues remains incomplete. Consequently, optimal dosing and scheduling in clinics are affected. With sequential radiolabeled mAb-based imaging, radiation dosing in tissues/organs can be calculated to provide a better assessment of mAb concentrations in tissues. This is the first pharmacokinetic model of 90Y-Ibritumomab tiuxetan (90Y-IT) in humans to be described, based on three-dimensional (3D) dosimetry using single-photon emission computed-tomography coupled with computed-tomography. 19 patients with follicular lymphoma were treated initially with 90Y-IT in the FIZZ trial. Based on a compartmental approach individualising the vascular compartment within studied organs, this study proposes a reliable pharmacokinetic (PK) five-compartment model replacing the currently used two-compartment model and constitutes a new direction for further research. This model provides exchange constants between the different tissues, Area Under the Curve of 111In-IT in blood (AUC) and Mean Residence Time (MRT) that have not been reported so far for IT. Finally, the elimination process appears to occur in a compartment other than the liver or the spleen and suggests the metabolism of mAbs may take place mainly on the vascular compartment level.
Collapse
Affiliation(s)
- F Morschhauser
- Univ. Lille, CHU Lille, EA 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associees, Lille, France. .,Haematology Department, Hôpital Claude Huriez, CHU Lille, F-59000, Lille, France.
| | - B Dekyndt
- Univ. Lille, CHU Lille, EA 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associees, Lille, France.,Pharmacy Institute, CHU Lille, F-59000, Lille, France
| | - C Baillet
- Univ. Lille, CHU Lille, EA 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associees, Lille, France.,Nuclear Medicine department, Hôpital Claude Huriez, CHU Lille, F-59000, Lille, France
| | - C Barthélémy
- Univ. Lille, CHU Lille, EA 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associees, Lille, France
| | - E Malek
- Univ. Lille, CHU Lille, EA 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associees, Lille, France
| | - J Fulcrand
- Univ. Lille, CHU Lille, EA 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associees, Lille, France
| | - P Bigot
- Univ. Lille, CHU Lille, EA 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associees, Lille, France
| | - D Huglo
- Nuclear Medicine department, Hôpital Claude Huriez, CHU Lille, F-59000, Lille, France
| | - B Décaudin
- Univ. Lille, CHU Lille, EA 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associees, Lille, France.,Pharmacy Institute, CHU Lille, F-59000, Lille, France
| | - N Simon
- Univ. Lille, CHU Lille, EA 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associees, Lille, France.,Pharmacy Institute, CHU Lille, F-59000, Lille, France
| | - P Odou
- Univ. Lille, CHU Lille, EA 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associees, Lille, France.,Pharmacy Institute, CHU Lille, F-59000, Lille, France
| |
Collapse
|
5
|
Covut F, Pinto R, Cooper BW, Tomlinson B, Metheny L, Malek E, Lazarus HM, de Lima M, Caimi PF. Nivolumab before and after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2017; 52:1054-1056. [PMID: 28346414 DOI: 10.1038/bmt.2017.44] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- F Covut
- Stem Cell Transplant Program, University Hospitals Seidman Cancer Center, Cleveland, OH, USA
| | - R Pinto
- Stem Cell Transplant Program, University Hospitals Seidman Cancer Center, Cleveland, OH, USA
| | - B W Cooper
- Stem Cell Transplant Program, University Hospitals Seidman Cancer Center, Cleveland, OH, USA.,Case Comprehensive Cancer Center, Cleveland, OH, USA
| | - B Tomlinson
- Stem Cell Transplant Program, University Hospitals Seidman Cancer Center, Cleveland, OH, USA.,Case Comprehensive Cancer Center, Cleveland, OH, USA
| | - L Metheny
- Stem Cell Transplant Program, University Hospitals Seidman Cancer Center, Cleveland, OH, USA.,Case Comprehensive Cancer Center, Cleveland, OH, USA
| | - E Malek
- Stem Cell Transplant Program, University Hospitals Seidman Cancer Center, Cleveland, OH, USA.,Case Comprehensive Cancer Center, Cleveland, OH, USA
| | - H M Lazarus
- Stem Cell Transplant Program, University Hospitals Seidman Cancer Center, Cleveland, OH, USA.,Case Comprehensive Cancer Center, Cleveland, OH, USA
| | - M de Lima
- Stem Cell Transplant Program, University Hospitals Seidman Cancer Center, Cleveland, OH, USA.,Case Comprehensive Cancer Center, Cleveland, OH, USA
| | - P F Caimi
- Stem Cell Transplant Program, University Hospitals Seidman Cancer Center, Cleveland, OH, USA.,Case Comprehensive Cancer Center, Cleveland, OH, USA
| |
Collapse
|
6
|
Malek E, Sendilnathan A, Yellu M, Petersen A, Fernandez-Ulloa M, Driscoll JJ. Metabolic tumor volume on interim PET is a better predictor of outcome in diffuse large B-cell lymphoma than semiquantitative methods. Blood Cancer J 2015. [PMID: 26207787 PMCID: PMC4526777 DOI: 10.1038/bcj.2015.51] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Affiliation(s)
- E Malek
- Hematology and Oncology, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA
| | - A Sendilnathan
- Division of Hematology and Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, USA
| | - M Yellu
- Division of Hematology and Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, USA
| | - A Petersen
- Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA
| | - M Fernandez-Ulloa
- Department of Nuclear Medicine, University of Cincinnati, Cincinnati, OH, USA
| | - J J Driscoll
- 1] Division of Hematology and Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, USA [2] The Vontz Center for Molecular Studies, University of Cincinnati College of Medicine, Cincinnati, OH, USA
| |
Collapse
|
7
|
Ferrer L, Malek E, Bodet-Milin C, Legouill S, Prangère T, Robu D, Jeans S, Tipping J, Huglo D, Carpentier P, Illidge T, Kraeber-Boderé F, Morschhauser F, Bardiès M. Comparisons of dosimetric approaches for fractionated radioimmunotherapy of non-Hodgkin lymphoma. Q J Nucl Med Mol Imaging 2012; 56:529-537. [PMID: 23358406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
AIM The aim of this study was to compare different dosimetric approaches on therapy naïve patients enrolled in a multicentre fractionated radioimmunotherapy trial, to determine which methodological approach correlates with bone marrow toxicity. METHODS Twenty-height non-Hodgkin lymphoma patients were treated with one or two fractions of 90Y-Ibritumomab-Tiuxetan (11.1 MBq/kg) 8 to 12 weeks apart in four different institutions. Quantitative imaging with 111In-Ibritumomab-Tiuxetan (185 MBq) was performed at 0, 1, 4 and 7 days after infusion, starting two weeks before the therapeutic administration. A whole-body (WB) CT scan was also acquired prior to the 111In-Ibritumomab injection, for attenuation correction purposes and was segmented to derive patient-specific organ masses. All dosimetry processing was centralized in a single institution. The first method (M_2D) was based on geometric mean WB scans, corrected for attenuation, scatter and organs superposition. The second method (M_2.5D) was based on the computed assisted matrix inversion approach and used segmented CT scans. The third method (M_3D) used iterative reconstruction of tomographic scans, corrected for attenuation, scatter and collimator response. Absorbed doses were estimated for lungs, liver, kidneys and spleen using MIRD S values adjusted for organ masses. Bone marrow (BM) absorbed doses were evaluated according to imaging methods (3) and compared to blood-based approaches. RESULTS For some patients, organ masses such as liver or spleen significantly differed from male/female reference masses, whereas lungs and kidneys masses were relatively constant. Except for lungs, absorbed doses estimated by M_2D were higher than those from M_2.5D and these, in turn, were higher that those calculated from M_3D (Wilcoxon P<8.6e-4). Median organ absorbed dose estimates were equivalent for both fractions except for the spleen. In fact, spleen absorbed doses for the second fraction were lower than those for the first fraction, regardless of the approach. Possible explanations are that patient spleen masses were kept constant for analysis of both fractions and/or that spleen uptake was lowered after the first fraction. Estimation of BM absorbed doses from blood sampling was unable to predict platelet toxicity, but image-based methods performed better. Additionally, for most organs, the absorbed dose delivered by the first fraction could predict that delivered by the second fraction. CONCLUSION These results confirm that different acquisition/processing protocols will lead to statistically different absorbed doses. Additionally, image-based dosimetric approaches are needed in order to correlate absorbed dose to bone marrow toxicity.
Collapse
Affiliation(s)
- L Ferrer
- ICO René Gauducheau, St Herblain, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Malek E, Lebecque P. [Etology and treatment of community acquired pneumonia in children]. J Pharm Belg 2007; 62:21-4. [PMID: 17508663] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/15/2023]
Abstract
In children under 5 years, most lower respiratory tract infections are caused by viruses and do not require antibiotics. This is true for almost all episodes of bronchitis and bronchiolitis but also for the majority of pneumonias. Atypical pneumonias due to Mycoplasma pneumoniae or Chlamydia pneumoniae predominate in older children while Streptococcus pneumoniae remains by far the most common cause of bacterial pneumonia. Diagnosis of pneumonia itself can be difficult and relies on a combination of clinical judgement and radiological and laboratory investigations. In real-life situations, etiologic agents are rarely identified, an issue further complicated by the possibility of mixed infections particularly in hospitalised children. Since viruses are often the sole cause of pneumonia in childhood, it is appropriate not to treat every child with antibiotics. However, when a bacterial origin can not be excluded, antibiotics efficient on Streptococcus pneumoniae are to be prescribed. Amoxicillin is the first choice empirical antibiotic treatment, having a higher efficacy on poorly sensitive pneumococcus than cephalosporins. Macrolides are indicated for the treatment of atypical pneumonia. Current immunisation strategies have decreased the number of bacterial pneumonias. However, there is some evidence that among hospitalised children the rate of complicated pneumonias is increasing with an emerging role of Streptococcus pneumoniae serotype 1, which is not covered in the 7-valent vaccine.
Collapse
Affiliation(s)
- E Malek
- Service de pédiatrie géenrale, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
| | | |
Collapse
|
9
|
Klös VHG, Jarofke D, Langner H, Siems H, Malek E. Die chemische und mikrobiologische Zusammensetzung der Panzernashornmilch (Fortsetzung). Reprod Domest Anim 1974. [DOI: 10.1111/j.1439-0531.1974.tb00359.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
10
|
|
11
|
Malek E. Correlation analyses of cercarial exposure, worm load and egg content in stools of dogs infected with Heterobilharzia americana. Z Tropenmed Parasitol 1969; 20:333-40. [PMID: 5380276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|